SAB Biotherapeutics, Inc. Common Stock (SABS) Stock
Fundamentals
Recent news

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
SABS

SAB Biotherapeutics Q2 Earnings Call Highlights
SAB Biotherapeutics Q2 Earnings Call Highlights
SABS

SAB Biotherapeutics Q1 Earnings Call Highlights
SAB Biotherapeutics Q1 Earnings Call Highlights
SABS
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
% positive news of 3 articles
published over the past 14 days
Latest news

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
SABS

SAB Biotherapeutics Q2 Earnings Call Highlights
SAB Biotherapeutics Q2 Earnings Call Highlights
SABS

SAB Biotherapeutics Q1 Earnings Call Highlights
SAB Biotherapeutics Q1 Earnings Call Highlights
SABS
About SAB Biotherapeutics, Inc. Common Stock
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Samuel J. Reich | CEO & Director | 1975 |
| Dr. Eddie Joe Sullivan Ph.D. | Co-Founder, President & Director | 1967 |
| Ms. Lucy To | Executive VP & CFO | 1986 |
| Dr. Christoph Bausch M.B.A., Ph.D. | Executive VP & COO | 1971 |
| Dr. Alexandra Kropotova M.B.A., M.D. | Executive VP & Chief Medical Officer | 1973 |
| Ms. Catherine DeRose | Vice President of Human Resources | — |
| Ms. Hua Wu Ph.D. | Senior Vice President of Product Development | — |
| Dr. Carlos N. Carillo M.Sc., Ph.D. | Senior Vice President of Regulatory Affairs | — |
| Ms. Angie Parizek | Senior Vice President of Clinical Operations | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
0 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.1 | -3.4 | +3.7 | +13.4 | -8.0 | -2.1 | -11.1 |



